Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 62
- Registration Number
- NCT02799238
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Ryhov hospital, Jönköping, Sweden
🇸🇪Skånes university hospital, Lund, Sweden
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Bevacizumab/IrinotecanBiological: ALECSAT
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 25
- Registration Number
- NCT02060955
- Locations
- 🇩🇰
Aalborg Universityhospital, Department of Oncology, Aalborg, Hobrovej 18-22, Denmark
🇩🇰Aarhus University Hospital, Department of Oncology, Aarhus, Nørrebrogade 44, Denmark
🇩🇰Odense University Hospital, Department of Oncology, Odense, Sdr. Boulevard 29, Denmark
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01984658
- Locations
- 🇩🇰
Kirurgisk afdeling K, Bispebjerg Hospital, Copenhagen, Denmark
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 23
- Registration Number
- NCT01588769
- Locations
- 🇩🇰
Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
- Conditions
- Hormone-refractory Prostate Cancer
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- CytoVac A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01422850
- Locations
- 🇩🇰
Department of Urology, Frederikssund, Denmark
- Prev
- 1
- 2
- Next